Novo Nordisk, Sanofi and Eli Lilly cut insulin prices and lose share in China’s latest cost squeeze
On the centennial of the discovery of insulin, China decided a round of price cuts on the diabetes therapy is due. As a result, foreign companies Novo Nordisk, Sanofi...
Continue Reading →
